Anti-VEGF Market Share
The Anti-VEGF Market share is concentrated among a few key players who have established a dominant position. Regeneron Pharmaceuticals is a major leader, largely due to its blockbuster drug Eylea (aflibercept), which commands a significant portion of the market in the U.S. and other key regions. Roche/Genentech, another dominant force, has a strong presence with its drugs Lucentis (ranibizumab) and Avastin (bevacizumab), which are used for both ophthalmic and oncological applications.
The market share is also influenced by the growing number of emerging players and the rapid introduction of biosimilars. Companies like Samsung Bioepis and Biogen have gained traction with their biosimilar versions of Lucentis and Eylea, which are creating increased competition and offering more affordable treatment options. While the larger pharmaceutical companies still hold the lion's share, the rise of biosimilars and new long-acting therapies is expected to shift the market dynamics. The competitive landscape is not static, and continuous innovation will be key for companies to maintain or gain market share in the coming years.